311 related articles for article (PubMed ID: 36327625)
21. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
Fenton MA; Tarantino P; Graff SL
Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
[TBL] [Abstract][Full Text] [Related]
22. Antibody-Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer.
Al Jarroudi O; El Bairi K; Curigliano G; Afqir S
Cancer Treat Res; 2023; 188():1-27. PubMed ID: 38175340
[TBL] [Abstract][Full Text] [Related]
23. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
Pondé N; Aftimos P; Piccart M
Curr Treat Options Oncol; 2019 Apr; 20(5):37. PubMed ID: 30931493
[TBL] [Abstract][Full Text] [Related]
24. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of sacituzumab govitecan in a patient with TNBC with early relapse after neoadjuvant chemotherapy.].
Carlino F; Feliciano S
Recenti Prog Med; 2024 Jun; 115(6):26e-30e. PubMed ID: 38853739
[TBL] [Abstract][Full Text] [Related]
26. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
27. Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond.
Barroso-Sousa R; Tolaney SM
BioDrugs; 2021 Mar; 35(2):159-174. PubMed ID: 33666903
[TBL] [Abstract][Full Text] [Related]
28. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
Zangardi ML; Spring LM; Nagayama A; Bardia A
Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322
[TBL] [Abstract][Full Text] [Related]
29. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
30. Role of sacituzumab govitecan in solid tumors.
Veeraballi S; Khawar Z; Aslam HM; Muzaffar M
J Oncol Pharm Pract; 2022 Oct; 28(7):1617-1623. PubMed ID: 35404158
[TBL] [Abstract][Full Text] [Related]
31. Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
Qu F; Lu R; Liu Q; Wu X; Huang X; Yin Y; Li W
Cancer; 2024 Apr; 130(S8):1392-1402. PubMed ID: 38271367
[TBL] [Abstract][Full Text] [Related]
32. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
Zardavas D
Expert Opin Investig Drugs; 2022 Jun; 31(6):633-644. PubMed ID: 35451891
[TBL] [Abstract][Full Text] [Related]
33. Future potential targets of antibody-drug conjugates in breast cancer.
Corti C; Boscolo Bielo L; Schianca AC; Salimbeni BT; Criscitiello C; Curigliano G
Breast; 2023 Jun; 69():312-322. PubMed ID: 36996620
[TBL] [Abstract][Full Text] [Related]
34. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
35. Antibody drug conjugates for patients with breast cancer.
Medford A; Spring LM; Moy B; Bardia A
Curr Probl Cancer; 2021 Oct; 45(5):100795. PubMed ID: 34635342
[TBL] [Abstract][Full Text] [Related]
36. Sacituzumab Govitecan-hziy in Breast Cancer.
Kwapisz D
Am J Clin Oncol; 2022 Jul; 45(7):279-285. PubMed ID: 35728046
[TBL] [Abstract][Full Text] [Related]
37. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J
Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724
[TBL] [Abstract][Full Text] [Related]
38. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
Nicolò E; Zagami P; Curigliano G
Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
[TBL] [Abstract][Full Text] [Related]
39. Trop-2 as a Therapeutic Target in Breast Cancer.
Sakach E; Sacks R; Kalinsky K
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497418
[TBL] [Abstract][Full Text] [Related]
40. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
Rugo HS; Bardia A; Tolaney SM; Arteaga C; Cortes J; Sohn J; Marmé F; Hong Q; Delaney RJ; Hafeez A; André F; Schmid P
Future Oncol; 2020 Apr; 16(12):705-715. PubMed ID: 32223649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]